Our development of FOL-014 has also opened new possibilities to add patent protection – and stakeholder value to our company. The diabetes area broadens our product portfolio and has an interesting market potential.
|Diabetes – application filed.||2017—2038||EP with the possibility of a PCT-application covering 152 countries.|
One of our objectives is to strengthen the patent applications through further pre-clinical trials and through promising research collaborations. Later on, we intend to find partners to further develop and commercialise the drug.